Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS.

Area of Science:

• Neuroimmunology
• Gastroenterology
• Pharmacology

Background:

• Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
• Gadolinium-enhanced MRI lesions indicate active inflammation in relapsing-remitting MS (RRMS).
• Interferon-alpha (IFN-alpha) is an immunomodulatory cytokine with parenteral administration used in MS treatment.

Purpose of the Study:

• To assess the safety and efficacy of orally administered human recombinant interferon-alpha2a (IFN-alpha2a) in patients with active RRMS.
• To determine if ingested IFN-alpha2a reduces the number of gadolinium-enhanced lesions on serial MRI.
• To evaluate changes in immune markers and adverse events associated with oral IFN-alpha2a treatment.

Main Methods:

• A randomized, placebo-controlled trial involving 30 patients with active RRMS.
• Patients received placebo, 10,000 IU, or 30,000 IU of ingested IFN-alpha2a on alternate days for 9 months.
• Monthly clinical examinations and cerebral MRI with gadolinium contrast were performed.

Main Results:

• No significant reduction in gadolinium-enhanced lesions was observed based on the primary outcome measure.
• Post hoc analysis indicated a potential treatment effect in the 10,000 IU group, with 73% fewer lesions at month 5 compared to placebo (p < 0.05).
• Decreased tumor necrosis factor-alpha secretion was noted; no significant differences in relapses, adverse events, or anti-IFN-alpha antibodies were found.

Conclusions:

• Oral IFN-alpha2a did not demonstrate efficacy based on the primary MRI outcome in active RRMS.
• Observed changes in immune response and potential effects in the lower dose group warrant further investigation.
• Oral administration of IFN-alpha2a appears safe and does not induce anti-IFN antibodies.